AsCNP/JSNP/JSCNP 2019

Session information

[AsCNP] Symposium

AsCNP » [AsCNP] Symposium

[AsCNP_S35] Symposium-35
Obsessive-compulsive disorder: clinical heterogeneity and innovative treatment approaches

Sat. Oct 12, 2019 2:50 PM - 4:30 PM Room 11 (502)

Organizer / Chair: ‌Chan-Hyung KIM (Department of Psychiatry, Yonsei University College of Medicine, Korea), Discussants: ‌Toshihide KUROKI (Department of Clinical Psychology, Kyushu University Graduate School of Human-Environment Studies, Japan), Taro KATO (Pharmacology Research Unit, Sumitomo Dainippon Pharma Co., Ltd., Japan)

Obsessive-compulsive (OC) symptoms are remarkably diverse, and the clinical presentations can vary both within and across patients over long period of time. This variability in the phenotypic expression has led to the hypothesis that obsessive-compulsive disorder (OCD) is a heterogeneous disorder and that this heterogeneity obscures the findings of clinical, natural history and treatment response studies. OCD is commonly considered as a heterogeneous condition with distinct neural correlates across symptom dimension. The precise causal factors for OCD are not known, however, decades of research have proposed abnormalities of cortico-striatal circuits that involve the orbitofrontal cortex, anterior cingulate cortex, thalamus and the striatum in the brain as a critical pathway involved in obsessions and the intimately linked compulsive-repetitive behaviors. A complete understanding of what comprises OCD will require a several different approaches. These approaches include (1) narrowing the phenotype to identify neurobiological basis of individual phenotypes in OCD (2) broadening the phenotype in OCD to include hoarding disorder (3) updating recent non-invasive treatment technique, such as neuromodulation for OCD and (4) challenging to manage OCD comorbid with schizophrenia and bipolar disorder, difficult-to-treat. it is hoped that the characterization of the pathophysiological mechanisms of OCD components and OC related conditions could contribute to the development of specific pharmacological and neuromodulatory therapies tailored to each of these conditions.